High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification (pages 1081–1089)
Anne Laprie, Jean Michon, Olivier Hartmann, Caroline Munzer, Marc-David Leclair, Carole Coze, Dominique Valteau-Couanet, Dominique Plantaz, Christian Carrie, Jean-Louis Habrand, Christophe Bergeron, Pascal Chastagner, Anne-Sophie Défachelles, Olivier Delattre, Valérie Combaret, Jean Bénard, Yves Pérel, Virginie Gandemer, Hervé Rubie and Neuroblastoma Study Group of the French Society of Pediatric Oncology
Article first published online: 16 JUL 2004 | DOI: 10.1002/cncr.20453
The authors compared the outcomes of two groups of children with localized neuroblastoma and MYCN amplification who received or did not receive postoperative high-dose chemotherapy (HDC) and stem cell rescue (SCR). The 6-year survival rate difference was highly significant between the group of children (n = 20 patients) who received conventional postoperative treatment (survival rate: 25% ± 10%) and the group of children (n = 12 patients) who received postoperative HDC, SCR, and radiotherapy (83% ± 10% survival; P = 0.004).